Nephrotoxic drugs;Nephrotoxische arzneimittel

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 45, 2005, Pages 2579-2584

  Czock, D ^a   Haussler U ^a   Aymanns, C ^a   Keller, Frieder ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; CISPLATIN; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSCARNET; HYDRALAZINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LITHIUM; METHOTREXATE; MITOMYCIN; OLANZAPINE; PARACETAMOL; PENICILLAMINE; PENICILLIN G; RIFAMPICIN; SULFONAMIDE; THIAZIDE DIURETIC AGENT; TRAMADOL; UNINDEXED DRUG;

ADULT; ANAMNESIS; CASE REPORT; CREATININE BLOOD LEVEL; DRUG SAFETY; ELECTROCARDIOGRAM; HEMODIALYSIS; HUMAN; INTERSTITIAL NEPHRITIS; LABORATORY TEST; MALE; MANIC DEPRESSIVE PSYCHOSIS; NEPHROTOXICITY; PATHOPHYSIOLOGY; REVIEW;

ANALGESICS; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; METALS, HEAVY;

EID: 27944440502     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922037     Document Type: Review

References (35)

1. Agrawal M, Stouffer GA. Contrast induced nephropathy after angiography. Am J Med Sci 2002; 323: 252-258
2. Anderson BJ, Woollard GA, Holford NHG. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol 2001; 57: 559-569
3. Bader BD, Berger ED, Heede MB et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004; 62: 1-7
4. Birck R, Krzossok S, Markowetz F et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603
5. Chang EJ, Mun KC. Effect of epigallocatechin gallate on renal function in cyclosporine-induced nephrotoxicity. Transplant Proc 2004; 36: 2133-2134
6. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11: 1795-1804
7. Deray G, Martinez F, Katlama C et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9: 316-321
8. Elseviers MM, Waller I, Nenoy D et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant 1995; 10: 808-814
9. Elseviers MM, De Broe ME. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance abuse? Drug Saf 1999; 20: 15-24
10. Fillastre JP, Druet P, Mery JP. Proteinuric nephropathies associated with drugs and substances of abuse. Dekker, New York, In The nephrotic syndrome (ed. Cameron JS, Glassock RJ). 1988: 697-744
11. Gitlin M. Lithium and the kidney: an updated review. Drug Saf 1999; 20: 231-243
12. Kadikoylu G, Bolaman Z, Demir S et al. The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum Exp Toxicol 2004; 23: 29-34
13. Kuypers DR, Neumayer HH, Pritsche L et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomised placebo-controlled 2-year study. Transplantation 2004; 78: 1204-1211
14. Lin J, Bonventre JV. Prevention of radiocontrast nephropathy. Curr Opin Nephrol Hypertens 2005; 14: 105-110
15. Lukas R, Eren A, Zellner D et al. Furosemide after contrast media does no harm to the kidneys and allows for preventive hydration. Perfusion 2003; 16: 326-333
16. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, 3rd Simonton CA, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004; 291: 2328-2334
17. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimes in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329-336
18. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11: 177-182
19. Nisar S, Feinfeld DA. N-acetylcysteine as salvage therapy in cisplatin nephrotoxicity. Ren Fail 2002; 24: 529-533
20. Nishino Y, Takemura S, Minamiyama Y et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin-induced nephrotoxicity in rats. Free Radic Res 2003; 37: 373-379
21. Olsen KM, Rudis MI, Rebuck JA et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004; 32: 1678-1682
22. Ortiz M, Mon C, Fernandez MJ et al. Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib. Nefrologia 2005; 25: 39-43
23. Parfrey PS, Griffiths SM, Barrett BJ et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320: 143-149
24. Parlakpinar H, Tasdemir S, Polat A et al. Protective effect of chelerythrine on gentamicin-induced nephrotoxicity. Cell Biochem Funct 2004
25. Potter JL, Jr. Krill CE. Acyclovir crystalluria. Pediatr Infect Dis 1986; 5: 710-712
26. Rudnick MR, Goldfarf S, Wexler I et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The lohexol Cooperative Study. Kidney Int 1995; 47: 254-261
27. Santoso JT, 3rd Lucci JA, Coleman RL et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomised trial. Cancer Chemother Pharmacol 2003; 52: 13-18
28. Sawyer MH, Webb DF, Balow JE et al. Acyclovir induced renal failure: clinical course and histology. Am J Med 1988; 84: 1067-1071
29. Schadeli F, Marti HP, Frey FJ et al. Population pharmacokinetic model to predict steady-state exposure to once-daily Cyclosporin microemulsion in renal transplant recipients. Clin Pharmacokinet 2002; 41: 59-69
30. Schwarz A. Systematik der Nephrotoxizität. Wissenschaftliche Verlags-gesellschaft, Stuttgart, In Nierenfunktion und Arzneimittel (ed. Deuber HJ, Keller F, Schwarz A). 2001: 150-259
31. Schwarz A, Krause PH, Kunzendorf U et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol 2003; 54: 179-190
32. Smith EJ, Light JA, Filo RS et al. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. J Am Med Assoc 1980; 244: 360-361
33. Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am J Med 2001; 1111: 521-527
34. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic contrast agent-induced reductions in renal functions by acetylcysteine. N Engl J Med 2000; 343: 180-184
35. World MJ, Stevens PE, Ashton MA et al. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996; 11: 614-621